arrow
Á

Álvaro Díaz-González

valdecilla research institute and marqués de valdecilla university hospital
H指数:18
被引数:1,056

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Revisiting Ferritin-IgG Score to Predict Complete Biochemical Response in Autoimmune Hepatitis

重新评估铁蛋白-IgG评分以预测自身免疫性肝炎的完全生化反应

2026-09-290
OAAI
Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes

原发性胆汁性胆管炎诊断时的脂肪肝疾病:与熊去氧胆酸反应和结局的关联

2026-06-050
OAAI
OPTICAL GENOME MAPPING IN MYELOFIBROSIS: ENHANCING PROGNOSTIC ACCURACY THROUGH HIGH-RESOLUTION GENOMIC PROFILING.

光学基因组作图在骨髓纤维化中的应用:通过高分辨率基因组分析提高预后准确性。

2025-10-300
OAAI
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis

持续正常转氨酶的自身免疫性肝炎患者中,孤立性IgG升高不影响其预后。

2025-08-290
OAAI
Unveiling Drug-Induced Autoimmune-Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study

揭示药物诱导的自身免疫样性肝炎在自身免疫性肝炎患者中的表现:一项多中心回顾性研究

2025-08-260
PRE
Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry
2024-05-296
PRE
Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study
2024-05-012
OAAI
Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy

不同治疗方式下肝硬化原发性胆汁性胆管炎患者失代偿事件的预测因素

2024-03-065
PRE
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso (lo)ne administration

布地奈德作为自身免疫性肝炎患者的一线治疗似乎不如标准泼尼松 (lo)ne给药

2023-01-0316
OA
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia
2022-07-0111
OAAI
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study

索拉非尼治疗肝移植术后复发性肝癌的回顾性研究

2021-09-1626
PREAI
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

索拉非尼早期腹泻作为考虑向二线药物早期迁移的标志

2021-07-061
OAAI
Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation
2021-03-010
PREAI